We are live on
!
Find out more
Loomis, Sayles & Company Portfolio holdings
AUM
$74.3B
1-Year Est. Return
24.01%
This Fund
S&P 500
This Quarter
Est. Return
+10.76%
1 Year Est. Return
+24.01%
3 Year Est. Return
+109.67%
5 Year Est. Return
+145.58%
10 Year Est. Return
+623.12%
AUM
$82.5B
AUM Growth
+$5.26B
(+6.8%)
Cap. Flow
-$2.02B
Cap. Flow
% of AUM
-2.45%
Top 10 Holdings %
Top 10 Hldgs %
38.94%
Holding
962
New
129
Increased
342
Reduced
292
Closed
136
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$429M |
| 2 |
Airbnb
ABNB
|
+$235M |
| 3 |
T-Mobile US
TMUS
|
+$156M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
+$139M |
| 5 |
CRISPR Therapeutics
CRSP
|
+$111M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Deere & Co
DE
|
+$488M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$222M |
| 3 |
Expeditors International
EXPD
|
+$191M |
| 4 |
Qualcomm
QCOM
|
+$187M |
| 5 |
CERN
Cerner Corp
CERN
|
+$171M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.12% |
| 2 | Consumer Discretionary | 15.99% |
| 3 | Communication Services | 13.72% |
| 4 | Healthcare | 12.84% |
| 5 | Industrials | 11.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
201
Rocket Pharmaceuticals
RCKT
$394M
| $39.8M | 0.05% |
899,510
-18,214
| -2% | -$791K |
|
202
Newmont
NEM
$119B
| $39.1M | 0.05% |
616,844
-165,444
| -21% | -$11.1M |
|
203
BioMarin Pharmaceuticals
BMRN
$12.4B
| $38.4M | 0.05% |
460,073
-55,826
| -11% | -$4.43M |
|
204
Nomad Foods
NOMD
$1.68B
| $38.3M | 0.05% |
1,353,863
+25,022
| +2% | +$736K |
|
205
PTC Therapeutics
PTCT
$6.12B
| $38.3M | 0.05% |
904,917
+1,951
| +0.2% | +$83.6K |
|
206
SM Energy
SM
$6.87B
| $38.2M | 0.05% |
+1,551,312
| New | +$30.1M |
|
207
Replimune Group
REPL
$1.01B
| $38.1M | 0.05% |
992,593
+215,411
| +28% | +$7.37M |
|
208
Arcosa
ACA
$7.11B
| $38.1M | 0.05% |
649,064
-3,541
| -0.5% | -$219K |
|
209
Globus Medical
GMED
$11.2B
| $38M | 0.05% |
490,138
+19,285
| +4% | +$1.37M |
|
210
Floor & Decor
FND
$6.68B
| $37.7M | 0.05% |
356,795
+14,043
| +4% | +$1.46M |
|
211
Champion Homes
SKY
$5.14B
| $37.2M | 0.05% |
698,461
+15,733
| +2% | +$742K |
|
212
Paylocity
PCTY
$7.98B
| $36.8M | 0.04% |
193,071
+7,585
| +4% | +$1.36M |
|
213
SI-BONE Inc
SIBN
$834M
| $36.6M | 0.04% |
1,164,188
+302,551
| +35% | +$9.78M |
|
|
SYNH
214
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $36.6M | 0.04% |
408,975
+16,144
| +4% | +$1.36M |
|
215
Morningstar
MORN
$7.53B
| $36.2M | 0.04% |
140,920
+5,524
| +4% | +$1.34M |
|
|
NVMI
216
Nova
NVMI
$12.5B
| $36.1M | 0.04% |
350,463
+13,780
| +4% | +$1.33M |
|
217
Home BancShares
HOMB
$6.18B
| $35.8M | 0.04% |
1,449,828
+76,754
| +6% | +$2.07M |
|
218
Oxford Industries
OXM
$552M
| $35.6M | 0.04% |
+360,101
| New | +$33.8M |
|
219
Vontier
VNT
$4.74B
| $35.4M | 0.04% |
1,086,314
+99,132
| +10% | +$3.27M |
|
220
Valvoline
VVV
$4.51B
| $35.2M | 0.04% |
1,083,357
+3,719
| +0.3% | +$116K |
|
|
BPMC
221
DELISTED
Blueprint Medicines
BPMC
| $34.8M | 0.04% |
395,368
-8,034
| -2% | -$736K |
|
222
Generac Holdings
GNRC
$12.5B
| $34.5M | 0.04% |
83,155
-26,535
| -24% | -$8.9M |
|
223
Trimble
TRMB
$13.9B
| $33.8M | 0.04% |
413,359
-128,507
| -24% | -$10.2M |
|
224
Inogen
INGN
$164M
| $33.6M | 0.04% |
+515,451
| New | +$32.6M |
|
225
Semtech
SMTC
$13B
| $33.2M | 0.04% |
483,112
+19,006
| +4% | +$1.26M |
|
Similar funds
CBU
BC
Loomis, Sayles & Company's Q2 2021 Portfolio in Review
As of Q2 2021, Loomis, Sayles & Company held 962 positions worth $82.5B, up 6.8% from $77.2B the previous quarter. Its ten largest holdings account for 39% of the portfolio.
Loomis, Sayles & Company's Q2 2021 filing shows 129 new, 342 increased, 292 reduced and 136 closed positions. Its largest new stake was Alnylam Pharmaceuticals: 946,065 shares worth $160M. The largest sale was Deere & Co, an estimated $488M.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 25% a quarter earlier, followed by Consumer Discretionary and Communication Services.
- Loomis, Sayles & Company's largest Q2 2021 buy was Alnylam Pharmaceuticals: 946,065 shares worth $160M.
- Loomis, Sayles & Company added most to Vertex Pharmaceuticals in Q2 2021, an estimated $429M increase.
- Loomis, Sayles & Company's biggest Q2 2021 reduction was Deere & Co, cutting an estimated $488M.
- Loomis, Sayles & Company fully exited Goosehead Insurance in Q2 2021, selling an estimated $66.6M.
- Loomis, Sayles & Company's ten largest holdings make up 39% of its $82.5B portfolio in Q2 2021.
- Loomis, Sayles & Company opened 129 new positions and closed 136 in Q2 2021.
- Loomis, Sayles & Company's portfolio value rose 6.8% quarter-over-quarter to $82.5B.
Based on Loomis, Sayles & Company's 13F filing for Q2 2021, filed 13 Aug 2021.